Company Profile

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets 19:53:32 02/07/2026 +04			5-day change	1st Jan Change
1.690 ^USD	+0.90%		-.--%	+14.19%

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-30	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI

Markets		Quality
OTC Markets	APTO	Delayed
Börse Stuttgart	LTI0	Delayed

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-30	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI
06-15	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
06-15	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
05-29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
05-29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
05-14	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
04-01	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Aptose Biosciences Inc. - Shareholder/Analyst Call
03-31	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
03-23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
03-23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT

03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
03-19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
11/06/24	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
10/11/23	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
11/08/23	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

Aptose Biosciences Inc. Stock OTC Markets

Stocks

APTO

CA03835T4081

Pharmaceuticals

Chart: Aptose Biosciences Inc.

Latest news: Aptose Biosciences Inc.

Last Transcript: Aptose Biosciences Inc.

Analysts' recommendations: Aptose Biosciences Inc.

Press Releases: Aptose Biosciences Inc.

News in other languages: Aptose Biosciences Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Aptose Biosciences Inc.

Other Pharmaceuticals

Company Profile

07-01	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
06-15	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
06-15	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
05-29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
05-14	Aptose Biosciences: Q1 Earnings Snapshot	AQ

12-05	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
12-05	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
09/09/23	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
08/09/23	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Current year	1.24	1.74
1 year	1.08	1.74
3 years	0.64	99.6
5 years	0.64	1,251
10 years	0.64	4,163.63

Manager	Title	Age	Since
C. Payne DFI	Director of Finance/CFO	63	27/06/2022
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	01/11/2019
Rafael Bejar CTO	Chief Tech/Sci/R&D Officer	54	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES INC.	+0.90%	-.--%	-	-	4.32M
ELI LILLY AND COMPANY	-0.01%	+1.69%	+63.50%	+117.58%	1,056B
JOHNSON & JOHNSON	-1.61%	-0.71%	+48.89%	+70.56%	655B
ABBVIE INC.	-1.12%	-0.45%	+19.35%	+72.93%	471B
ROCHE HOLDING AG	-1.72%	-4.25%	+37.79%	+39.89%	342B
NOVARTIS AG	-0.40%	+4.12%	+22.89%	+29.04%	277B
ASTRAZENECA PLC	-0.51%	-1.05%	+12.98%	+12.92%	257B
AMGEN INC.	+1.32%	+7.75%	+55.19%	+56.43%	226B
GILEAD SCIENCES, INC.	-0.61%	+0.48%	+34.95%	+100.58%	189B
NOVO NORDISK A/S	-0.24%	-3.21%	-27.79%	-61.37%	170B
Average	-0.40%	+0.52%	+29.75%	+48.73%	404.77B
Weighted average by Cap.	-0.63%	+0.76%	+39.85%	+68.92%

1 day	+0.90%
3 months	+9.03%
6 months	+4.86%
Current year	+14.19%